We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 23, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CLAY-BASED AROMATISED THERAPEUTIC COMPOSITION
Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
MACROCYCLIC LRRK2 KINASE INHIBITORS
PROCESS FOR THE SYNTHESIS OF THERAPEUTIC PEPTIDES
Pharmaceutical composition for a sustained release of lanreotide
Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AQUEOUS GELLING COMPOSITIONS OF SOLUBLE ACTIVE PHARMACEUTICAL PEPTIDES PROVIDING MODIFIED RELEASE
AQUEOUS SUSTAINED RELEASE COMPOSITIONS OF LHRH ANALOGUES
PHARMACEUTICAL COMPOSITION FOR A SUSTAINED RELEASE OF LANREOTIDE
PROCESS FOR THE PREPARATION OF POLYMERS WITH VARIOUS STRUCTURES AND AMIDE INITIATING
NEW OCTAPEPTIDIC COMPOUNDS AND THEIR USE IN THERAPY
COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD1 AND/OR PDL1 INHIBITOR, FOR USE AS A MEDICAMENT
SUSTAINED RELEASE FORMULATIONS COMPRISING VERY LOW MOLECULAR WEIGHT POLYMERS
COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT